Immunologic Articles

Articles

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

We reviewed the literature on adjuvant therapies for patients with high risk localized kidney cancer following surgical resection. In this analysis we merge 2 recently published prospective trials with conflicting results within the context of their respective designs.
Published March 19, 2018
Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.

The identification of protein biomarkers to guide treatment decisions regarding adjuvant therapies for high-risk non-muscle-invasive bladder cancer (NMIBC) has been of increasing interest. Evidence of the impact of tumor suppressor gene product p53 and cell proliferation marker Ki-67 on oncologic outcomes in bladder cancer patients at highest risk of recurrence and progression is partially contradictory.
Published February 1, 2018
Purified protein derivative skin test prior to bacillus Calmette-Guérin therapy may have therapeutic impact in patients with non-muscle-invasive bladder cancer.

To investigate the clinical impact of the purified protein derivative (PPD) skin test prior to bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant BCG therapy.
Published January 18, 2018